The FDA authorized Diphenyhydramine-D, an anti-itch drug based on Apricus Biosciences' NexACT proprietary technology. The over-the-counter medicine contains zinc acetate and diphenhydramine hydrochloride.
Published in Brief:
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan